Colchicine, a microtubule-disassembling drug, in the therapy of cardiovascular diseases
Colchicine, a microtubule-disassembling drug, in the therapy of cardiovascular diseases
复制标题
DOI：
10.1002/cbin.10988
复制
发表时间：
2018-08-01
影响因子：
3.9
通讯作者：
Chaldakov, George N.
中科院分区：
文献类型：
--
作者：
Chaldakov, George N.
秋水仙碱在100多年前就被分离出来，数千年来一直被用于治疗疼痛和肿胀。它是从那个时期已知的为数不多的药物之一，其使用一直延续到现代。在过去的几十年里，在知识的进展（i）细胞骨架微管（M？），和（ii）秋水仙碱（一种经典的MT-分解（微管蛋白-靶向）剂）的抗炎和抗纤维化作用已经导致这种非常古老的药物的潜在新用途扩展到急性痛风性关节炎和家族性地中海热之外。在这里，简而言之，我提出了保加利亚的贡献可能的潜力，秋水仙碱在治疗心血管疾病，已经出现在20世纪70年代初在实验室的电子显微镜，医学研究所，瓦尔纳，保加利亚，研究血管平滑肌细胞的分泌功能。从那时起，低剂量秋水仙碱（0.5-1.0mg/天）越来越多地口服用于治疗心血管疾病，如急性冠状动脉综合征，术后房颤（心脏手术），心包炎，心脏肥大相关的心力衰竭，血管成形术后再狭窄和全身性坏死性血管炎。因此，秋水仙碱可能是目前心血管疾病治疗的一个新工具。这只是一个MT分解药物的例子。在获得对这种抗微管蛋白药理学和治疗的真实的信心之前，肯定需要进一步的研究。这可能导致开发新的和更具体的抗微管蛋白的心血管疾病。
Colchicum autumnale, from which colchicine has been isolated more than 100 years ago, has been used as a treatment for pain and swelling for thousands of years. It is one of the few drugs known from that time period whose use has survived to modernity. Over the past decades, advances in the knowledge of (i) cytoskeletal microtubules (M?), and (ii) anti-inflammatory and anti-fibrotic effects of colchicine, a classical MT-disassembling (tubulin-targeting) agent, have led to potential new uses for this very old drug extended beyond acute gouty arthritis and familial Mediterranean fever. Here, in brief, I present the Bulgarian contribution to possible potential of colchicine in the therapy of cardiovascular diseases that has emerged in the early 1970s in the Laboratory of Electron Microscopy, Medical Institute, Varna, Bulgaria, studying the secretory function of vascular smooth muscle cells. From this time onward, low-dose colchicine (0.5-1.0mg/daily) was increasingly administered orally for therapy of cardiovascular diseases such as acute coronary syndromes, postoperative atrial fibrillation (in cardiac surgery), pericarditis, cardiac hypertrophy-associated heart failure, restenosis after angioplasty, and systemic necrotizing vasculitis. Thus, colchicine might be a new tool in the present therapeutic armamentarium for cardiovascular diseases. It is simply an example of MT-disassembling drugs. Further studies will definitely be required before gaining real confidence in this kind of antitubulin pharmacology and therapy. This may lead to developing new and more specific antitubulins for cardiovascular diseases.